 |
|
Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
Yong Won Choi, Jin-Hyuk Choi
Korean J Intern Med. 2017;32(3):422-428. Published online 2017 Mar 30 DOI: https://doi.org/10.3904/kjim.2016.190
|
|
Citations to this article as recorded by
 Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset
Ki Hyeong Lee, Byoung Chul Cho, Myung-Ju Ahn, Yun-Gyoo Lee, Youngjoo Lee, Jong-Seok Lee, Joo-Hang Kim, Young Joo Min, Gyeong-Won Lee, Sung Sook Lee, Kyung-Hee Lee, Yoon Ho Ko, Byoung Yong Shim, Sang-We Kim, Sang Won Shin, Jin-Hyuk Choi, Dong-Wan Kim, Eun
Cancer Research and Treatment.2024; 56(1): 48. CrossRef Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study
Tae-Hwan Kim, Jin-Hyuk Choi, Mi Sun Ahn, Hyun Woo Lee, Seok Yun Kang, Yong Won Choi, Young Wha Koh, Seung-Soo Sheen
BMC Cancer.2024;[Epub] CrossRef Osimertinib Induces the Opposite Effect of Proliferation and Migration in the Drug
Resistance of EGFR-T790M Non-small Cell Lung Cancer Cells
Rou-Hsin Wang, Chien-Jen Chang, Chien-Hung Chen, Kuang-Kai Liu, Jui-I Chao
Anti-Cancer Agents in Medicinal Chemistry.2023; 23(11): 1309. CrossRef The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients
Adam Szpechcinski, Mateusz Florczuk, Katarzyna Duk, Aneta Zdral, Stefan Rudzinski, Maciej Bryl, Grzegorz Czyzewicz, Piotr Rudzinski, Wlodzimierz Kupis, Emil Wojda, Dorota Giedronowicz, Renata Langfort, Aleksander Barinow-Wojewodzki, Tadeusz Orlowski, Joan
Cellular and Molecular Life Sciences.2019; 76(18): 3641. CrossRef
|